Merck & Company Inc (MRK)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
MRK
Merck & Company Inc
$120.79
+1.41%
HEALTHCARE · Cap: $283.78B
TAK
Takeda Pharmaceutical Co Ltd ADR
$15.47
+0.97%
HEALTHCARE · Cap: $49.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 6751% more annual revenue ($4.51T vs $65.77B). MRK leads profitability with a 13.6% profit margin vs -3.4%. TAK appears more attractively valued with a PEG of 0.40. TAK earns a higher WallStSmart Score of 57/100 (C).
MRK
Hold50
out of 100
Grade: D+
TAK
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-40.6%
Fair Value
$80.96
Current Price
$120.79
$39.83 premium
Intrinsic value data unavailable for TAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 330.2% YoY
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
3.9% revenue growth
ROE of 2.5% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.40 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
MRK profiles as a value stock while TAK is a turnaround play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.22 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
TAK scores higher overall (57/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?